TIDMAREC

RNS Number : 5055D

Arecor Therapeutics PLC

29 June 2021

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

Director Dealing

Cambridge, UK, 29(th) June 2021. Arecor Therapeutics plc (AIM: AREC) , the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Susan Lowther, Chief Financial Officer, has purchased 12,515 ordinary shares of GBP0.01 each in the capital of the Company ("Ordinary Shares") at a price of 235 pence per Ordinary Share.

Following the transaction, the total beneficial interest of Susan Lowther is 110,681 Ordinary Shares, representing 0.40% of the total voting rights.

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                  www.arecor.com 
 Dr Sarah Howell, Chief Executive         Tel: +44 (0) 1223 426060 
  Officer                                  Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer   Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
 Mo Noonan, Communications                Tel: +44 (0) 7876 444977 
                                           Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD       Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela       Tel: +44 (0) 20 3709 5700 
  Gray                                     Email: arecor@consilium-comms.com 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat(TM) technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

For further details please see our website, www.arecor.com

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
        Details of the person discharging managerial responsibilities/person 
    1    closely associated 
 a)     Name                             Susan Lowther 
       -------------------------------  -------------------------------------- 
 2      Reason for the notification 
       ----------------------------------------------------------------------- 
 a)     Position/status                  Chief Financial Officer 
       -------------------------------  -------------------------------------- 
 b)     Initial notification/Amendment   Initial notification 
       -------------------------------  -------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       ----------------------------------------------------------------------- 
 a)     Name                             Arecor Therapeutics plc 
       -------------------------------  -------------------------------------- 
 b)     LEI                              98450093D12I3A8DDD58 
       -------------------------------  -------------------------------------- 
 4      Details of the transaction(s): section to be repeated for 
         (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions 
         have been conducted 
       ----------------------------------------------------------------------- 
 a)     Description of the               Ordinary Shares 
         financial instrument, 
         type of instrument 
       -------------------------------  -------------------------------------- 
 b)     Identification Code              GB00BMWLM973 
       -------------------------------  -------------------------------------- 
 c)     Nature of the transaction        Purchase of shares 
       -------------------------------  -------------------------------------- 
 
 d)     Price(s) and volume(s)            235 pence and 12,515 Ordinary Shares 
       -------------------------------  -------------------------------------- 
 e)     Aggregated information           N/A 
         - Aggregated volume 
         - Aggregated price 
       -------------------------------  -------------------------------------- 
 f)     Date of the transaction          29 June 2021 
       -------------------------------  -------------------------------------- 
 g)     Place of the transaction         London Stock Exchange, AIM 
       -------------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGZGZVMLFGMZM

(END) Dow Jones Newswires

June 29, 2021 07:05 ET (11:05 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Arecor Therapeutics Charts.